Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trialDavid J. Kuter, Janet L. Nichol, Carlos Grande et al.|The Lancet|2008Cited by 862
AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITPJames B. Bussel, Janet L. Nichol, David J. Kuter et al.|New England Journal of Medicine|2006Cited by 530
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-ISrđan Verstovšek, H. Kantarjian, Ruben A. Mesa et al.|Haematologica|2013Cited by 162
Improved quality of life for romiplostim‐treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo‐controlled trialsJames N. George, Martin R. Schipperus, Susan D. Mathias et al.|British Journal of Haematology|2008Cited by 146
Long-Term Dosing of AMG 531 in Thrombocytopenic Patients with Immune Thrombocytopenic Purpura: 48-Week Update.David J. Kuter, Janet L. Nichol, James B. Bussel et al.|Blood|2006Cited by 30